Masimo Receives FDA 510(k) Clearance for smartSedLine™ to Advance Brain Health During Anesthesia

The Technology Helps Clinicians Assess Changes in Brain Activity Faster During Induction of Anesthesia and More Consistently Under Low Electroencephalography (EEG) Power to Better Inform Individualized Patient Care

IRVINE, Calif., Nov. 18, 2026 /PRNewswire/ — Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for smartSedLine™, a next-generation brain function monitoring solution designed to help clinicians understand changes in a patient’s response to anesthesia faster and more consistently, enabling more individualized care throughout a procedure. The solution provides clinicians with more responsive and stable information about brain activity, including during induction and when electroencephalography (EEG) signals are low, helping them make more informed decisions about depth of sedation. The milestone marks Masimo’s seventh FDA clearance in 2026, reflecting the company’s continued innovation in patient monitoring.

Sign up for Blog Updates